UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 10,972	$ 12,349
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	530	465
Amortization	1,548	4,824
Provision for (recovery of) losses on accounts receivable	(6)	(31)
Amortization of Right of Use Assets	38	39
Deferred income taxes	(417)	(284)
Stock-based compensation expense	184	153
Tax benefit attributable to exercise of stock options	20	12
Changes in operating assets and liabilities
Accounts receivable and other receivables	(306)	2,133
Inventories	508	(925)
Prepaid expenses and other current assets	54	19
Accounts payable	229	(712)
Accrued expenses	(1,460)	(1,093)
Total adjustments	922	4,600
Net cash provided by operating activities	11,894	16,949
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment	(221)	(549)
Intangible assets	(5)	0
Proceeds from sale of property and equipment	27	0
Net cash used in investing activities	(199)	(549)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock - options	390	117
Common stock purchased and retired	(13,259)	0
Payment of dividends	(3,222)	(3,211)
Net cash used in financing activities	(16,091)	(3,094)
Effect of exchange rate changes on cash	(20)	(149)
Net increase/(decrease) in cash and cash equivalents	(4,416)	13,157
Cash at beginning of period	92,868	75,052
Cash at end of period	88,452	88,209
Cash paid during the period for income taxes	3,713	3,489
Cash paid during the period for interest	$ 0	$ 0